- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
August 27, 2015 (HealthDay News) -- Even brief spurts of exercise may benefit children, researchers report.
Their study of 28 healthy, normal-weight children found that doing three minutes of moderate-intensity walking every half hour over three hours of sitting led to lower levels of blood sugar and insulin, compared to another day when the children sat for three hours straight.
August 27, 2015 (MobiHealthNews) - San Diego, California-based Dexcom has received FDA 510(k) clearance for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system.
Unlike the company's previous connected CGM devices, the G5 Mobile CGM System has Bluetooth built right in to the transmitter and sends glucose data directly to a smartphone, so users don't have to carry a separate receiver device. Data from the CGM can be sent to
August 26, 2015 (Healio) - A modest, but not statistically significant, relationship was found between HbA1c levels and cardiovascular events in people with type 2 diabetes, according to recent study findings published in Diabetes Care.
There was no difference in relationship among people with or without clinical manifestation of vascular disease, according to the researchers.
August 26, 2015 (HealthDay News) -- Type 2 diabetes can be misdiagnosed in patients with hemoglobin (Hb) Wayne, according to a case report published online Aug. 20 in Diabetes Care.
Elona Turley, M.D., from the University of Alberta in Edmonton, Canada, and colleagues describe the case of a 66-year-old Caucasian female who was referred for specialist follow-up of treatment-refractory type 2 diabetes, which was diagnosed based on two consecutive HbA1c results >6.5 percent. The patient had glyc
Novo Nordisk Plans 2 Billion US Dollar Investment in New Production Facilities in Clayton, North Carolina and MåLøv, Denmark
August 26, 2015 (Novo Nordisk) - Novo Nordisk plans to invest an estimated 2 billion US dollars over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.
In a separate company announcement today, Novo Nordisk announced a decision to initiate phase 3a development of oral semaglutide, a GLP-1 analogue formulated as a once-daily tablet for th